Citation Impact
Citing Papers
Next-Generation-Sequencing-Based Hospital Outbreak Investigation Yields Insight into Klebsiella aerogenes Population Structure and Determinants of Carbapenem Resistance and Pathogenicity
2019
Rhizobium induces DNA damage in Caenorhabditis elegans intestinal cells
2019 StandoutNobel
Vaginal microbiome of reproductive-age women
2010 Standout
Effects of Cardiac Resynchronization Therapy With or Without a Defibrillator on Survival and Hospitalizations in Patients With New York Heart Association Class IV Heart Failure
2006
A unique mechanism of β-blocker action: Carvedilol stimulates β-arrestin signaling
2007 StandoutNobel
Impact of Implantable Cardioverter-Defibrillator, Amiodarone, and Placebo on the Mode of Death in Stable Patients With Heart Failure
2009
Antibiotic Resistance Caused by Gram‐Negative Multidrug Efflux Pumps
1998
Antimicrobial therapy for patients with severe sepsis and septic shock: An evidence-based review
2004
Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis
2004
Influence of patient factors and ablative technologies on outcomes of radiofrequency ablation of intra-atrial re-entrant tachycardia in patients with congenital heart disease
2002
Equivalent arrhythmic risk in patients recently diagnosed with dilated cardiomyopathy compared with patients diagnosed for 9 months or more
2006
AmpG, a signal transducer in chromosomal β‐lactamase induction
1993
ChromosomalampCgenes inEnterobacterspecies other thanEnterobacter cloacae, and ancestral association of the ACT-1 plasmid-encoded cephalosporinase toEnterobacter asburiae
2002
Inducible amp C β-lactamase producing gram-negative bacilli from blood stream infections: Frequency, antimicrobial susceptibility, and molecular epidemiology in a national surveillance program (SCOPE)
1997
von Willebrand Factor–Cleaving Protease in Thrombotic Thrombocytopenic Purpura and the Hemolytic–Uremic Syndrome
1998 Standout
Implantable Defibrillators for the Prevention of Mortality in Patients With Nonischemic Cardiomyopathy
2004
Genetic Evaluation of Cardiomyopathy—A Heart Failure Society of America Practice Guideline
2009
The clinical course of patients with implantable cardioverter-defibrillators: Extended experience on clinical outcome, device replacements, and device-related complications
2015
New Mechanisms of Bacterial Resistance to Antimicrobial Agents
1991
Multicenter Automatic Defibrillator Implantation Trial–Cardiac Resynchronization Therapy (MADIT‐CRT): Design and Clinical Protocol
2005
Antimicrobial-Drug Resistance
1996
Experiences of Driving and Driving Restrictions in Recipients With an Implantable Cardioverter Defibrillator-The Patient Perspective
2010
ICD Implantation and Arrhythmia‐Free Survival in Patients with Depressed LV Function Following Surgery for Valvular Heart Disease
2008
Intrinsic resistance of Mycobacterium tuberculosis to clarithromycin is effectively reversed by subinhibitory concentrations of cell wall inhibitors
2000
Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency
2009 Standout
Prophylactic implantable cardioverter defibrillator treatment in patients with end-stage heart failure awaiting heart transplantation
2013
Percutaneous Repair or Surgery for Mitral Regurgitation
2011 Standout
Outbreaks in Health Care Settings
2016
A Prediction Rule to Identify Low-Risk Patients with Community-Acquired Pneumonia
1997 Standout
Disseminated Infection with Rapidly Growing Mycobacteria
1993
Recommendations from the Heart Rhythm Society Task Force on Device Performance Policies and Guidelines
2006
Time to Clinical Stability in Patients Hospitalized With Community-Acquired Pneumonia
1998
Plasmid-encoded functions compensate for the biological cost of AmpC overexpression in a clinical isolate of Salmonella typhimurium
2004
Enterobacter aerogenes and Enterobacter cloacae; versatile bacterial pathogens confronting antibiotic treatment
2015
Predictors of sudden cardiac death after mustard or senning repair for transposition of the great arteries
2004
Cardiac-Resynchronization Therapy for the Prevention of Heart-Failure Events
2009 Standout
2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults
2009 Standout
Class Restriction of Cephalosporin Use to Control Total Cephalosporin Resistance in Nosocomial <EMPH TYPE="ITAL">Klebsiella</EMPH>
1998
The Effect of Cardiac Resynchronization on Morbidity and Mortality in Heart Failure
2005 Standout
Survival in biopsy-proven myocarditis: A long-term retrospective analysis of the histopathologic, clinical, and hemodynamic predictors
2006
ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities
2008 Standout
Severe Sepsis and Septic Shock
2013 Standout
Frequency and Causes of Implantable Cardioverter-Defibrillator Therapies: Is Device Therapy Proarrhythmic?
2006
What are the consequences of the disappearing human microbiota?
2009
Implantable Cardioverter Defibrillators in Patients with Valvular Cardiomyopathy
2012
Clinical significance of beta-lactamase induction and stable derepression in gram-negative rods
1987
Role of the Microbiota in Immunity and Inflammation
2014 Standout
Medical therapy versus implantable cardioverter -defibrillator in preventing sudden cardiac death in patients with left ventricular systolic dysfunction and heart failure: A meta-analysis of >35,000 patients
2014
DIAGNOSIS AND TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION
1997 Standout
HRS/ACC/AHA Expert Consensus Statement on the Use of Implantable Cardioverter-Defibrillator Therapy in Patients Who Are Not Included or Not Well Represented in Clinical Trials
2014
Incidence of and Risk Factors for Sudden Cardiac Death in Children With Dilated Cardiomyopathy
2012
Multidrug-Resistant Enterobacter cloacae Complex Emerging as a Global, Diversifying Threat
2019
Effect of Cardiac and Noncardiac Conditions on Survival After Defibrillator Implantation
2007
An Outbreak ofMycobacterium chelonaeInfection Following Liposuction
2002
Disseminated Infection Due to Rapidly Growing Mycobacteria in Immunocompetent Hosts Presenting with Chronic Lymphadenopathy: A Previously Unrecognized Clinical Entity
2000
A Prospective Randomized Study of Inpatient IV Antibiotics for Community-Acquired Pneumonia
1996
Extended Broad-Spectrum -Lactamases Conferring Transferable Resistance to Newer -Lactam Agents in Enterobacteriaceae: Hospital Prevalence and Susceptibility Patterns
1988 Standout
The Structural Basis for the Action of the Antibiotics Tetracycline, Pactamycin, and Hygromycin B on the 30S Ribosomal Subunit
2000 StandoutNobel
Enterobacter Bacteremia: Clinical Features and Emergence of Antibiotic Resistance during Therapy
1991
The Role of the Wearable Cardioverter Defibrillator in Clinical Practice
2014
Genomic Diversity within the Enterobacter cloacae Complex
2008
Implantable Cardioverter-Defibrillator Shocks
2013
Antibiotics for pneumonia therapy
1994
The challenge of emerging and re-emerging infectious diseases
2004 StandoutNature
The Cost Effectiveness of Implantable Cardioverter-Defibrillators
2006
The Entirely Subcutaneous Implantable Cardioverter-Defibrillator
2012
Blockage of the transduction channels of hair cells in the bullfrog's sacculus by aminoglycoside antibiotics
1989
The Microbial Genetics of Antibiotic Cycling
2000
Bacterial Vaginosis Is a Strong Predictor ofNeisseria gonorrhoeaeandChlamydiatrachomatisInfection
2003
ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: Executive Summary
2008
Usefulness of Sleep-Disordered Breathing to Predict Occurrence of Appropriate and Inappropriate Implantable-Cardioverter Defibrillator Therapy in Patients With Implantable Cardioverter-Defibrillator for Primary Prevention of Sudden Cardiac Death
2013
Risk stratification for implantable cardioverter defibrillator therapy: the role of the wearable cardioverter-defibrillator
2013
Occurrence and detection of AmpC beta-lactamases among Gram-negative clinical isolates using a modified three-dimensional test at Guru Tegh Bahadur Hospital, Delhi, India
2003
Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005)
2005 Standout
Increased von Willebrand factor binding to platelets in single episode and recurrent types of thrombotic thrombocytopenic purpura
1998
Comparison of Benefit and Mortality of Implantable Cardioverter–Defibrillator Therapy in Patients Aged ≥75 Years Versus Those <75 Years
2011
Iatrogenic outbreak of M. chelonae skin abscesses
1996
Use of a Continuous-Flow Device in Patients Awaiting Heart Transplantation
2007 Standout
Trends in Prevalence and Outcome of Heart Failure with Preserved Ejection Fraction
2006 Standout
Analyses of ampC gene expression in Serratia marcescens reveal new regulatory properties
2003
Novel R-factor borne β-lactamase of Escherichia coli confering resistance to cephalosporins
1987
Cost-Effectiveness of Implantable Cardioverter–Defibrillators
2005
Health and Economic Outcomes of the Emergence of Third-Generation Cephalosporin Resistance in Enterobacter Species
2002
Mycobacterium simiaePseudo‐outbreak Resulting from a Contaminated Hospital Water Supply in Houston, Texas
2002
Carvedilol's antiarrhythmic properties: Therapeutic implications in patients with left ventricular dysfunction
2005
Selecting Patients for Discussion of the ICD as Primary Prevention for Sudden Death in Heart Failure
2006
Wearable defibrillator use in heart failure (WIF): results of a prospective registry
2012
Late Gadolinium Enhancement by Cardiovascular Magnetic Resonance Heralds an Adverse Prognosis in Nonischemic Cardiomyopathy
2008
Frequency of Cardiac Death in Children With Idiopathic Dilated Cardiomyopathy
2009
Addendum to “Personal and Public Safety Issues Related to Arrhythmias that May Affect Consciousness: Implications for Regulation and Physician Recommendations: A Medical/Scientific Statement from the American Heart Association and the North American Society of Pacing and Electrophysiology”
2007
Guidelines for the management of adult lower respiratory tract infections
2005
Amiodarone or an Implantable Cardioverter–Defibrillator for Congestive Heart Failure
2005 Standout
Sudden Cardiac Death Risk Stratification in Patients With Nonischemic Dilated Cardiomyopathy
2014
Rapid Development of Ciprofloxacin Resistance in Methicillin-Susceptible and -Resistant Staphylococcus aureus
1991
Identification of Low-Risk Hospitalized Patients With Pneumonia
1994
Staphylococcus aureusInfections
1998 Standout
How the ear's works work
1989 StandoutNature
Extension of resistance to cefepime and cefpirome associated to a six amino acid deletion in the H-10 helix of the cephalosporinase of anEnterobacter cloacaeclinical isolate
2001
Prophylactic implantable cardioverter-defibrillator therapy in patients with left ventricular systolic dysfunction
2004
Antibodies to von Willebrand Factor–Cleaving Protease in Acute Thrombotic Thrombocytopenic Purpura
1998 Standout
Use of implantable cardioverter-defibrillators for primary prevention in older patients: A systematic literature review and meta-analysis
2011
Antibiotic failure mediated by a resistant subpopulation in Enterobacter cloacae
2016
Myocarditis
2009 Standout
Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms
2010 Standout
Diagnosis and Treatment of Disease Caused by Nontuberculous Mycobacteria
1990 Standout
An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases
2007 Standout
Guidelines for the Management of Adults with Community-acquired Pneumonia
2001 Standout
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease
2012 Standout
beta-Lactamases in laboratory and clinical resistance
1995
Inhibition of Neisseria gonorrhoeae by Lactobacillus Species That Are Commonly Isolated from the Female Genital Tract
2002
The population dynamics of antimicrobial chemotherapy
1997
TRANSFERABLE ENZYMATIC RESISTANCE TO THIRD-GENERATION CEPHALOSPORINS DURING NOSOCOMIAL OUTBREAK OF MULTIRESISTANT KLEBSIELLA PNEUMONIAE
1987
ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult
2005 Standout
Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC beta-lactamase, and the foss of an outer membrane protein
1997
Sudden Cardiac Death in Adult Congenital Heart Disease
2012
ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death--executive summary: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society
2006
Comparison of screening methods for detection of extended-spectrum beta-lactamases and their prevalence among blood isolates of Escherichia coli and Klebsiella spp. in a Belgian teaching hospital
1997
Sulfonamide-containing regimens for disease caused by rifampin-resistant Mycobacterium kansasii.
1987
Role ofampDHomologs in Overproduction of AmpC in Clinical Isolates ofPseudomonas aeruginosa
2008
Mycobacterium chelonaeWound Infections after Plastic Surgery Employing Contaminated Gentian Violet Skin-Marking Solution
1987
23S rRNA base pair 2057–2611 determines ketolide susceptibility and fitness cost of the macrolide resistance mutation 2058A→G
2005 StandoutNobel
A Major Outbreak of Severe Acute Respiratory Syndrome in Hong Kong
2003 Standout
Epidemiology of Drug Resistance: Implications for a Post—Antimicrobial Era
1992 StandoutScience
β-Lactamases Responsible for Resistance to Expanded-Spectrum Cephalosporins in Klebsiella pneumoniae , Escherichia coli , and Proteus mirabilis Isolates Recovered in South Africa
1998
Meta-analysis: Age and Effectiveness of Prophylactic Implantable Cardioverter-Defibrillators
2010
Treatment of Nonpulmonary Infections Due to Mycobacterium fortuitum and Mycobacterium chelonei on the Basis of in Vitro Susceptibilities
1985
Ceftazidime resistance in Hafnia alvei
1993
Occurrence and detection of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae at a veterans medical center: seek and you may find
1997
Implantable Cardioverter Defibrillator Therapy in Adults With Congenital Heart Disease
2011
Mycobacterial isolations in young adults with cystic fibrosis.
1984
Effect of Amiodarone and Sotalol on Ventricular Defibrillation Threshold
2006
Activities of Imipenem and Cephalosporins against Clonally Related Strains of Escherichia coli Hyperproducing Chromosomal β-Lactamase and Showing Altered Porin Profiles
2000
Molecular Basis of Bacterial Outer Membrane Permeability Revisited
2003 Standout
Cefepime: the next generation?
1993
The roles of residues Tyr150, Glu272, and His314 in class C β‐lactamases
1996
Bacillus pumilus in the induction of clindamycin-associated enterocolitis in guinea pigs
1982
Detection and clinical significance of extended-spectrum beta-lactamases in a tertiary-care medical center
1997
Survey of Klebsiella pneumoniae Strains Producing Extended-Spectrum β-Lactamases: Prevalence of SHV-12 and SHV-2a in Korea
1998
NOSOCOMIAL OUTBREAKS/PSEUDO OUTBREAKS CAUSED BY NONTUBERCULOUS MYCOBACTERIA
1998
Resistance to Cefamandole: Derepression of -Lactamases by Cefoxitin and Mutation in Enterobacter cloacae
1982
OXA-11, an extended-spectrum variant of OXA-10 (PSE-2) beta-lactamase from Pseudomonas aeruginosa
1993
Visualization of mycobacterial membrane dynamics in live cells
2017 StandoutNobel
Emergence of Resistance to Imipenem During Therapy for Pseudomonas aeruginosa Infections
1986
2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults
2009
2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults
2009
AmpC β-Lactamases
2009 Standout
Diversity and Proliferation of Metallo-β-Lactamases: a Clarion Call for Clinically Effective Metallo-β-Lactamase Inhibitors
2018
ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death
2006
Canadian Guidelines for the Initial Management of Community-Acquired Pneumonia: An Evidence-Based Update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society
2000
American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society Scientific Statement on Noninvasive Risk Stratification Techniques for Identifying Patients at Risk for Sudden Cardiac Death
2008
Type I -Lactamases of Gram-Negative Bacteria: Interactions with -Lactam Antibiotics
1986
Characterization of a novel extended-spectrum beta-lactamase from Pseudomonas aeruginosa
1993
Imipenem- and meropenem-resistant mutants of Enterobacter cloacae and Proteus rettgeri lack porins
1991
Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications
1997
Can Results Obtained with Commercially Available MicroScan Microdilution Panels Serve as an Indicator of β-Lactamase Production among Escherichia coli and Klebsiella Isolates with Hidden Resistance to ExpandedSpectrum Cephalosporins and Aztreonam?
1998
Novel Fluorogenic Substrates for Imaging β-Lactamase Gene Expression
2003 StandoutNobel
Adaptive and Maladaptive Cardiorespiratory Responses to Continuous and Intermittent Hypoxia Mediated by Hypoxia-Inducible Factors 1 and 2
2012 StandoutNobel
Appropriate and Inappropriate Ventricular Therapies, Quality of Life, and Mortality Among Primary and Secondary Prevention Implantable Cardioverter Defibrillator Patients
2005
Role of a cefoxitin-inducible beta-lactamase in a case of breakthrough bacteremia
1980
2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death
2015 Standout
Cloning and Characterization of a Chromosomal Class C β-Lactamase and Its Regulatory Gene in Laribacter hongkongensis
2005
Use of Microdilution Panels with and without β-Lactamase Inhibitors as a Phenotypic Test for β-Lactamase Production among Escherichia coli , Klebsiella spp., Enterobacter spp., Citrobacter freundii , and Serratia marcescens
1999
Novel plasmid-mediated beta-lactamase (TEM-10) conferring selective resistance to ceftazidime and aztreonam in clinical isolates of Klebsiella pneumoniae
1989
Detection of Extended-Spectrum β-Lactamases in Clinical Isolates of Enterobacter cloacae and Enterobacter aerogenes
2000
Prevalence of Newer β-Lactamases in Gram-Negative Clinical Isolates Collected in the United States from 2001 to 2002
2006
American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society Scientific Statement on Noninvasive Risk Stratification Techniques for Identifying Patients at Risk for Sudden Cardiac Death
2008
Occurrence of Newer β-Lactamases in Klebsiella pneumoniae Isolates from 24 U.S. Hospitals
2002
Current mechanisms of resistance to antimicrobial agents in microorganisms causing infection in the patient at risk for infection
1984
Detection of extended-spectrum-beta-lactamase-producing members of the family Enterobacteriaceae with Vitek ESBL test
1996
Advanced Heart Failure Treated with Continuous-Flow Left Ventricular Assist Device
2009 Standout
Computationally designed peptide macrocycle inhibitors of New Delhi metallo-β-lactamase 1
2021 StandoutNobel
Consensus statement of the European Heart Rhythm Association: updated recommendations for driving by patients with implantable cardioverter defibrillators
2009
Risk Factors for Emergence of Resistance to Broad-Spectrum Cephalosporins among Enterobacter spp
2001
Evolution of plasmid-coded resistance to broad-spectrum cephalosporins
1985
Pathological Ventricular Remodeling
2013
ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities
2008 Standout
Diverse potential of beta-lactamase inhibitors to induce class I enzymes
1990
Comparative characterization of the cephamycinase blaCMY-1 gene and its relationship with other beta-lactamase genes
1996
Fibrosis — A Common Pathway to Organ Injury and Failure
2015 Standout
Management of Implantable Cardioverter Defibrillators in End-of-Life Care
2004
The Crisis in Antibiotic Resistance
1992 StandoutScience
Activity of cefepime and carbapenems in experimental pneumonia caused by porin-deficient Klebsiella pneumoniae producing FOX-5 β-lactamase
2005
Epidemiology and Successful Control of a Large Outbreak Due to Klebsiella pneumoniae Producing ExtendedSpectrum β-Lactamases
1998
Role of beta-lactam hydrolysis in the mechanism of resistance of a beta-lactamase-constitutive Enterobacter cloacae strain to expanded-spectrum beta-lactams
1985
Clinical Usefulness of Amikacin and Doxycycline in the Treatment of Infection Due to Mycobacterium fortuitum and Mycobacterium chelonei
1981
Identification of a New Allelic Variant of theAcinetobacter baumanniiCephalosporinase, ADC-7 β-Lactamase: Defining a Unique Family of Class C Enzymes
2005
Beta-lactamases and detection of beta-lactam resistance in Enterobacter spp
1997
Epidemiology of infection by nontuberculous mycobacteria
1996
TLA-1: a New Plasmid-Mediated Extended-Spectrum β-Lactamase from Escherichia coli
2000
Model System To Evaluate the Effect ofampDMutations on AmpC-Mediated β-Lactam Resistance
2006
Trapping of nonhydrolyzable cephalosporins by cephalosporinases in Enterobacter cloacae and Pseudomonas aeruginosa as a possible resistance mechanism
1982
Selection during Cefepime Treatment of a New Cephalosporinase Variant with Extended-Spectrum Resistance to Cefepime in an Enterobacter aerogenes Clinical Isolate
2004
An SHV-Derived Extended-Spectrum β-Lactamase in Pseudomonas aeruginosa
1999
Induction and Evasion of Host Defenses by Type 1-Piliated Uropathogenic Escherichia coli
1998 StandoutScience
Carbapenem Resistance in a Clinical Isolate of Enterobacter aerogenes Is Associated with Decreased Expression of OmpF and OmpC Porin Analogs
2002
Clavulanate Induces Expression of the Pseudomonas aeruginosa AmpC Cephalosporinase at Physiologically Relevant Concentrations and Antagonizes the Antibacterial Activity of Ticarcillin
1999
Transferable Mechanisms of Quinolone Resistance from 1998 Onward
2019
Surveillance of Community-Based Reservoirs Reveals the Presence of CTX-M, Imported AmpC, and OXA-30 β-Lactamases in Urine Isolates of Klebsiella pneumoniae and Escherichia coli in a U.S. Community
2008
Roles of β-Lactamases and Porins in Activities of Carbapenems and Cephalosporins against Klebsiella pneumoniae
1999
Hemorrhagic Colitis Associated with a RareEscherichia coliSerotype
1983 Standout
In vivo selection of porin-deficient mutants of Klebsiella pneumoniae with increased resistance to cefoxitin and expanded-spectrum-cephalosporins
1996
Activity of sulbactam in combination with ceftriaxone in vitro and in experimental endocarditis caused by Escherichia coli producing SHV-2-like beta-lactamase
1990
The Clinical Presentation, Diagnosis, and Therapy of Cutaneous and Pulmonary Infections Due to the Rapidly Growing Mycobacteria, M. fortuitum and M. chelonae
1989
Occurrence and Detection of AmpC Beta-Lactamases among Escherichia coli , Klebsiella pneumoniae , and Proteus mirabilis Isolates at a Veterans Medical Center
2000
ampR Gene Mutations That Greatly Increase Class C β-Lactamase Activity in Enterobacter cloacae
2000
Resistance to cefotaxime and seven other beta-lactams in members of the family Enterobacteriaceae: a 3-year survey in France
1992
Mycobacterium fortuitum bacteremia in patients with cancer and long-term venous catheters
1987
AmpC Disk Test for Detection of Plasmid-Mediated AmpC β-Lactamases in Enterobacteriaceae Lacking Chromosomal AmpC β-Lactamases
2005
Lung Infections Associated with Cystic Fibrosis
2002 Standout
An overview of nosocomial infections, including the role of the microbiology laboratory
1993
Enterobacter spp.: Update on Taxonomy, Clinical Aspects, and Emerging Antimicrobial Resistance
2019
Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae
1985
Extended-Spectrum β-Lactamases in the 21st Century: Characterization, Epidemiology, and Detection of This Important Resistance Threat
2001 Standout
Enterobacter cloacae Complex: Clinical Impact and Emerging Antibiotic Resistance
2012
Antimicrobial Resistance in ESKAPE Pathogens
2020 Standout
Emergence of Antibiotic Resistance during Therapy for Infections Caused by Enterobacteriaceae Producing AmpC β-Lactamase: Implications for Antibiotic Use
2007
Detection of Plasmid-Mediated AmpC β-Lactamase Genes in Clinical Isolates by Using Multiplex PCR
2002 Standout
Late Gadolinium Enhancement on Cardiac Magnetic Resonance Predicts Adverse Cardiovascular Outcomes in Nonischemic Cardiomyopathy
2013
Works of William E. Sanders being referenced
Cycling of antibiotics: an approach to circumvent resistance in specialized units of the hospital
1996
Radiofrequency catheter ablation of supraventricular tachycardia substrates after mustard and senning operations for d-transposition of the great arteries
2000
Oral ofloxacin for the treatment of acute bacterial pneumonia: Use of a nontraditional protocol to compare experimental therapy with “usual care” in a multicenter clinical trial
1991
Prophylactic Defibrillator Implantation in Patients with Nonischemic Dilated Cardiomyopathy
2004
Clinical importance of inducible beta-lactamases in gram-negative bacteria
1987
Patients With Recently Diagnosed Nonischemic Cardiomyopathy Benefit From Implantable Cardioverter-Defibrillators
2006
Inducible -Lactamases: Clinical and Epidemiologic Implications for Use of Newer Cephalosporins
1988
Efficacy, Safety, and Potential Economic Benefits of Oral Ciprofloxacin in the Treatment of Infections
1988
A Pilot Study of Antibiotic Cycling in a Hematology-Oncology Unit
2000
Meropenem: activity against resistant Gram-negative bacteria and interactions with -lactamases
1989
-Lactam Resistance in Gram-Negative Bacteria: Global Trends and Clinical Impact
1992
Antimicrobial Resistance with Focus on β-Lactam Resistance in Gram-Negative Bacilli
1997
Piperacillin/Tazobactam: A Critical Review of the Evolving Clinical Literature
1996
Efficacy of Cefepime in the Treatment of Infections Due to Multiply Resistant Enterobacter Species
1996
Evidence for multiple forms of type I chromosomal beta-lactamase in Pseudomonas aeruginosa
1986
Ability of the VITEK 2 Advanced Expert System To Identify β-Lactam Phenotypes in Isolates of Enterobacteriaceae and Pseudomonas aeruginosa
2000
USA resistance patterns among UTI pathogens
1994
Susceptibility of Organisms in the Mycobacterium fortuitum Complex to Antituberculous and Other Antimicrobial Agents
1977
Potential Impact of the VITEK 2 System and the Advanced Expert System on the Clinical Laboratory of a University-Based Hospital
2001
Enterobacter spp.: pathogens poised to flourish at the turn of the century
1997
Characterization of beta-lactamases in situ on polyacrylamide gels
1986
Infection Due to Organisms of the Mycobacterium fortuitum Complex after Augmentation Mammaplasty: Clinical and Epidemiologic Features
1983
Thrombotic thrombocytopenia with von Willebrand factor deficiency induced by botrocetin. An animal model.
1988
In Vitro Activity of Furazlocillin (Bay k 4999) Compared with Those of Mezlocillin, Piperacillin, and Standard Beta-Lactam Antibiotics
1979
Resistance to Cefamandole: A Collaborative Study of Emerging Clinical Problems
1982
Beta-lactamase production in members of the family Enterobacteriaceae and resistance to beta-lactam-enzyme inhibitor combinations
1990
Toxicity of Antibacterial Agents: Mechanism of Action on Mammalian Cells
1979
Influence of clindamycin on derepression of beta-lactamases in Enterobacter spp. and Pseudomonas aeruginosa
1983
Synergistic activities of clarithromycin and antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis
1995
Bacterial Interference. II. Role of the Normal Throat Flora in Prevention of Colonization by Group A Streptococcus
1973
Role of beta-lactamases and outer membrane proteins in multiple beta-lactam resistance of Enterobacter cloacae
1985
Fluoroquinolone resistance in staphylococci: new challenges.
1995
Comparison of BL-S786 with cephalothin, cefamandole and cefoxitin in vitro and in treatment of experimental infections in mice.
1978
In Vitro Studies with Sch 21420 and Sch 22591: Activity in Comparison with Six Other Aminoglycosides and Synergy with Penicillin Against Enterococci
1978
Cefepime-Aztreonam: a Unique Double β-Lactam Combination for Pseudomonas aeruginosa
1998
Antagonism of carbenicillin and cefamandole by cefoxitin in treatment of experimental infections in mice
1982
Heterogeneity of class I beta-lactamase expression in clinical isolates of Pseudomonas aeruginosa
1988
Microbial Resistance to Newer Generation f3-lactam Antibiotics: Clinical and Laboratory Implications
1985
Emergence of Resistance During Therapy with the Newer -Lactam Antibiotics: Role of Inducible -Lactamases and Implications for the Future
1983
Thrombotic Thrombocytopenia Induced in Dogs and Pigs
1995
Activity of Gentamicin against Mycobacteria In Vitro and against Mycobacterium tuberculosis in Mice
1971
In vitro antagonism of beta-lactam antibiotics by cefoxitin
1982
Inhibition of Neisseria gonorrhoeae by aerobic and facultatively anaerobic components of the endocervical flora: evidence for a protective effect against infection
1978
Emergence of Resistance to Cefamandole: Possible Role of Cefoxitin-Inducible Beta-Lactamases
1979
Selection of multiple antibiotic resistance by quinolones, beta-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes
1984
Activity of amikacin against mycobacteria in vitro and in murine tuberculosis
1982